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Abstract 
Antiphospholipid syndrome (APS) is an autoimmune condition characterized by the presence of antiphospholipid 
antibodies (aPL) in subjects presenting with thrombosis and/or pregnancy loss. The currently used classification 
criteria were updated in the international consensus held in Sidney in 2005. Vascular events seem to result of local 
procoagulative alterations upon triggers influence (the so called “second-hit theory”), while placental thrombosis and 
complement activation seem to lead to pregnancy morbidity. The laboratory tests suggested by the current classifica-
tion criteria include lupus anticoagulant, a functional coagulation assay, and anticardiolipin and anti-β2-glycoprotein-I 
antibodies, generally detected by solid phase enzyme-linked immunosorbent assay. The real challenge for treating 
physicians is understanding what is the actual weight of aPL in provoking clinical manifestations in each case. As 
thrombosis has a multi-factorial cause, each patient needs a risk-stratified approach. In this review we discuss the role 
of thrombotic risk assessment in primary and secondary prevention of venous and arterial thromboembolic disease in 
patients with APS, focusing on new antibody specificities, available risk scoring models and new coagulation assays.
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Background
The strive for personalised medicine can be traced in 
its origin to Hippocrates’ times: the assessment of the 
four humours—blood, phlegm, yellow bile and black 
bile—were essential to determine the correct treatment 
for each individual patient. Nowadays, the emphasis 
on disease prediction and prevention remains the main 
hallmark and challenge of individualised and personal-
ised medicine and is largely dependent on advances in 
research and published literature. One of the most ubiq-
uitous examples to personalise medicine is the develop-
ment of risk stratification or scoring models in order to 
predict the development of any given clinical outcome or 
disease.
The eagerness to develop and validate reliable scor-
ing models for the prediction of clinical outcomes in 
order to improve individual clinical care has motivated 
researchers within the field of autoimmune diseases to 
propose useful scoring models [1–4]. Especially in areas 
with a variety of clinical effectors and outcome variables, 
solid scoring systems are essential to provide a valuable 
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guidance in clinical practice to advise clinicians to the 
right treatment strategy.
The antiphospholipid syndrome (APS) is a systemic 
autoimmune disease, which is defined by the presence of 
thromboses and/or obstetric morbidity in patients persis-
tently positive for antiphospholipid antibodies (aPL). The 
classification criteria for APS have been outlined in the 
original Sapporo criteria, and have more recently been 
updated in the Sydney criteria [5] (Table 1).
aPL comprehends a heterogeneous group of cir-
culating immunoglobulins including lupus antico-
agulant (LA), anticardiolipin antibodies (aCL) and 
anti-β2glycoprotein-I (anti-β2GPI). Their persistent pres-
ence is related to diverse clinical phenomena including 
arterial and venous thrombosis, pregnancy complications 
and other common clinical manifestations such as livedo 
reticularis or thrombocytopenia. As the presence of aPL 
does not always lead to thrombotic events in every indi-
vidual with aPL, aPL are necessary, but not sufficient for 
clinical manifestations such as thromboembolic events 
or pregnancy morbidity. A “second hit theory” has been 
proposed, suggesting that other factors may trigger a 
clinical manifestation in individuals with aPL [6, 7].
Shi et al. studied the prevalence of LA and aCL in 499 
healthy Australian blood donors and found LA to have 
a prevalence of 3.6 % and aCL, 4.6 % [8], whereas 1 % of 
healthy control patients in the Leiden Thrombophilia 
study were found to have LA and 3.6 %, anti- β2GPI anti-
bodies [9]. The prevalence of aPL is higher in patients with 
other autoimmune conditions such as rheumatoid arthri-
tis or systemic lupus erythematosus (SLE), where up to 
40 % are persistently positive for aPL [10, 11]. Given their 
heterogeneity, their combinations and titres researchers 
have focused on exploring their link to different risks of 
clinical outcomes [12–15]. Furthermore, scoring models 
for the use in aPL positive individuals and patients with 
APS to predict the risk of thrombosis have been devel-
oped and validated by different groups [1, 2, 16, 17].
In this review we discuss the role of thrombotic risk 
assessment for venous and arterial thromboembolic dis-
ease in aPL-positive patients, focusing on new antibodies 
specificities, available risk scoring models and new coag-
ulation assays. A comprehensive analysis of the therapeu-
tic options for the management of aPL-positive patients 
is beyond the scope of this review; detailed information 
about current and potential future management strate-
gies can be found elsewhere [6].
Clinical manifestations of APS
APS is widely considered as the major acquired thrombo-
philia, which can affect any vascular bed (arterial, venous 
and the microvasculature). This may explain the vari-
ety of clinical manifestations described in APS patients. 
Albeit most of the clinical manifestations can be attrib-
uted to underlying thrombosis, inflammation, comple-
ment, platelet activation and macrophages have been 
shown to play crucial roles in the pathophysiology of the 
syndrome [6].
In a European cohort of 1000 APS patients, deep vein 
thrombosis (DVT) and pulmonary embolism (PE) were 
the most frequent clinical manifestations of the syn-
drome, whereas the most frequent arterial manifestations 
are neurological, such as stroke or transient ischemic 
attacks (TIA) [18]. Other neurological features include 
migraine headaches, memory loss and epilepsy. Throm-
bocytopenia and livedo reticularis are the most impor-
tant haematological and dermatological characteristics, 
respectively, and can be found in up to 20  % of APS 
patients [18].
Pregnancy morbidity includes unexplained fetal death, 
premature birth before 34  weeks of gestation due to 
severe pre-eclampsia, eclampsia or placental insuf-
ficiency or recurrent first trimester miscarriage. Pre-
eclampsia, premature birth or fetal loss are the most 
common manifestations and occur in 10–20  % of APS 
pregnancies [18].
Table 1 APS classification criteria, modified from Miyakis et al. [5]
Vascular thrombosis: ≥1 Clinical episode of arterial, venous or small vessel thrombosis. Thrombosis must be objectively confirmed. For histopatho-
logical confirmation, thrombosis must be present without inflammation of the vessel wall
Pregnancy morbidity: 1. ≥1 Unexplained death of a morphologically normal fetus ≥10 weeks of gestation
2. ≥1 Premature delivery of a morphologically normal fetus <34 weeks gestation because of:
   Severe pre-eclampsia or eclampsia defined according to standard definition
   Recognised features of placental insufficiency
3. ≥3 Unexplained consecutive miscarriages <10 weeks gestation, with maternal and paternal factors (anatomic, hormonal or 
chromosomal abnormalities) excluded
Laboratory criteria: The presence of antiphospholipid antibodies (aPL), on two or more occasions at least 12 weeks apart and no more than 5 years 
prior to clinical manifestations, as demonstrated by ≥1 of the following
   Presence of lupus anticoagulant in plasma
   Medium to high-titre anticardiolipin antibodies (>40 GPL or MPL, or >99th ‰) of IgG or IgM isoforms
   Anti-β2 glycoprotein-I antibody (anti-β2GPI) of IgG or IgM present in plasma
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Laboratory testing for aPL
aPL can be detected with three tests, all of which should 
be performed in any individual patient before the pres-
ence of aPL can be excluded or confirmed. The assays 
comprise test for the presence of lupus anticoagulant, 
anticardiolipin antibodies and anti-β2GPI [19, 20]. Indi-
viduals may be positive for one, two or three of these 
tests and are in the literature referred to as single, double 
or triple positive, respectively.
Lupus anticoagulant testing
LA is a functional assay measuring the ability of aPL to 
prolong phospholipid—dependent clotting assays. LA 
testing has been difficult to standardise, and no single 
test appears to be adequate, indicating the heterogeneity 
of different individuals aPL. As no coagulation test has 
100  % sensitivity, the 2009 Scientific and Standardisa-
tion Committee of the International Society on Throm-
bosis and haemostasis guidelines recommend two assays 
of different assay principle, the diluted Russell viper 
venom (dRVVT) test and a sensitive activated partial 
thromboplastin time (aPTT), with silica as an activa-
tor because of its sensitivity for LA [19]. According to 
the updated guidelines, the laboratory detection of LA 
should be based on the following criteria: (1) prolonga-
tion of phospholipid dependent clotting test, in particu-
lar when the phospholipid content of test system is low; 
(2) lack of correction of the prolonged clotting time by 
addition of a small amount of normal plasma (thereby to 
exclude factors deficiency); (3) correction by the presence 
of high concentration of phospholipid such as the use 
of platelet fragments, which will remove all the aPL, or 
by the use of a reagent that is poorly responsive for LA 
effect [19]. Similarly, current guidelines for LA detec-
tion recommend mixing test interpretation with either 
a mixing test-specific cut-off (MTC) or index of circu-
lating anticoagulant (ICA) [19]. Very recently, Moore 
et  al. [21] retrospectively applied MTC and ICA assess-
ment to raw data of 350 LA positive plasmas from non-
anticoagulated patients to compare detection rates of 
inhibition. They concluded that it is valuable to maximise 
mixing test interpretation as the dilution can lead to false 
negative results. Consequently, MTC is superior to ICA 
in detecting the in vitro inhibition of LA and might be a 
useful tool when assessing the risk in patients suspected 
for APS.
Anticardiolipin antibodies
aCL are usually detected by either radioimmunoassay 
or ELISA, using cardiolipin as the solid phase antigen. 
Serum is used for the aCL assays. IgG, IgM and/or IgA 
isotypes concentrations are expressed as GPL, MPL and/
or IgA units, respectively, where 1 unit represents the 
binding activity of 1 mg/ml of affinity purified aCL anti-
body. aCL IgG and IgM are currently part of the APS 
classification criteria [5], whereas the clinical value of 
aCL IgA remains subject of discussion as outlined below.
In general, positive LA tests are more specific for the 
APS, whereas aCL are more sensitive [9, 17]. The speci-
ficity of aCL for APS increases with the titre and is higher 
for the IgG than for the IgM isotype. However, some 




The development of anti-β2GPI immunoassays followed 
the observation that many aCL are directed to an epitope 
on β2-glycoprotein. However, in patients with clinical 
features of APS, anti-β2GPI antibodies are rarely the sole 
antibodies detected [15].
The β2GPI has five homologous domains (D1 to D5) 
and recently several studies focused their attention on 
the epitope distribution of anti-β2GPI antibodies, in 
order to identify the pathogenic specificities [22]. The 
main epitope that has been found to be associated with 
APS involves regions of D1 [23]. Recent promising data 
support the association between anti-β2GPI-D1 and 
APS clinical manifestation. Recent studies have found 
that patients with multiple aPL have a higher prevalence 
and higher titers of anti-β2GPI-D1 antibodies [22, 23]. 
International multi-centre evaluations have recently 
confirmed the preliminary reports supporting the 
associations between an history of thrombosis (mostly 
venous) and anti-β2GPI-D1 antibodies (reviewed in 
[24]). Taken the above together, anti-β2GPI-D1 anti-
bodies might be a promising biomarker for risk assess-
ment in APS. Further studies are warranted to validate 
this hypothesis.
IgA aPL isotypes
To date, no conclusive prospective study has offered a 
clear view on the usefulness of IgA aPL antibodies test-
ing. IgA aPL antibodies have a low prevalence and in 
most cases they are found along with other aPL, but they 
have failed to enhance the diagnostic accuracy when rou-
tinely tested [25].
To date, the use of IgA isotypes for both aCL and anti-
β2GPI are not a part of the routine diagnostic algorithm 
[20]. However some data suggested a role of isolated 
positivity for IgA anti-β2GPI with clinical APS symptoms 
might help to identify additional patients, recommend-
ing this tests when other aPL are negative. Based on the 
present evidence IgA aPL testing should be considered 
for thrombotic assessment risk only in selected patients, 
in particular when other aPL tests are negative, in the 
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presence of clinical APS signs and/or symptoms, mainly 
associated with SLE [20].
Non criteria aPL
Antiprothrombin antibodies
The role of aPL assays for the detection of autoantibod-
ies to phospholipids other than criteria antiphospholipid 
antibodies (for example anti-prothrombin or anti-phos-
phatidylserine) is an ongoing subject of debate. These 
antibodies are directed to negatively charged phospho-
lipids other then cardiolipin. Specifically, antibodies to 
prothrombin can be detected by directly coating pro-
thrombin on irradiated ELISA plates (aPT) or by using 
the phosphatidylserine/prothrombin complex as antigen 
(aPS/PT) [26]. Although these antibodies can co-exist 
in the same patient, they are two distinct populations of 
antibodies. In fact, aPS/PT (rather than aPT) has been 
shown to help to establish the diagnosis of APS and the 
associated risk for both arterial and/or venous throm-
bosis or pregnancy morbidity [27]. Their clinical impor-
tance is far from being fully explored, but the presence of 
these other aPL antibodies might represent a new tool for 
risk stratification, especially for those patients negative 
for the classic aPL.
Anti‑phosphatidylethanolamine antibody
In solid assays, sera from patients with APS usually react 
to negatively charged phospholipids (PL) and PL cofac-
tors such as β2-glycoprotein I (β2GPI). Binding to non 
negative charged PL (such as neutral PL, e.g. phosphati-
dylethanolamine) is less frequently observed [28].
Phosphatidylethanolamine (PE) is one of the main lipid 
components of the cell membranes, being mostly located 
in the inner leaflet [28]. In 1989 Staub et al. [28] reported 
the first case of primary APS whereby a LA was accom-
panied not by an aCL, but by an antibody to PE (aPE).
The clinical significance of aPE in patients with the 
thrombosis and/or pregnancy morbidity but negative for 
criteria aPL (so-called seronegative APS) is a very hot 
topic under investigation. Hirmerova et  al. [29] showed 
that in 140 patients with venous thromboembolism, of 
non-criteria aPL antibodies, only aPE was significantly 
more prevalent compared to controls, with minor over-
lapping with the criteria aPL. Moreover, aPE antibod-
ies were associated with a higher risk of thrombosis in a 
multicentre study including 270 patients with thrombotic 
disease and 236 matched controls [30]. Of note, more 
than 60  % of 40 aPE-positive patients were negative for 
the APS laboratory criteria. Similar results were found 
by the same group [31]. The screening for IgG, IgM and 
IgA aPE, seems to increase the diagnostic yield in APS 
[32], particularly when traditional laboratory criteria for 
APS are lacking [33]. After more than 25 years from the 
first description of aPE antibodies in a patient with pri-
mary APS [34], the clinical value of these antibodies in 
individuals with unexplained thrombosis and pregnancy 
morbidity remains intriguing. Whilst solid evidence 
supporting the inclusion of aPE as classification criteria 
for APS is lacking, one may consider testing for aPE in 
patients with clinical features suggestive of APS without 
the presence of criteria aPL [35].
Anti‑vimentin antibodies
Vimentin is a ubiquitous protein part of the cytoskeleton 
intermediate filament structure. Anti-vimentin antibod-
ies were first described in patients with SLE, and they 
reportedly exhibit significant association with the pres-
ence of aCL [36]. Albeit anti-vimentin antibodies have 
been shown to activate platelets and leukocytes with 
increased expression of P-selectin, fibrinogen, TF, and 
platelet-leukocyte conjugates [37], the diagnostic role of 
in the context of APS is still largely undefined. Ortona 
et al. [38] demonstrated that vimentin is capable of bind-
ing cardiolipin in vitro, possibly as a result of electrostatic 
interaction between its positively charged amino acids 
and the negatively charged amino acids of cardiolipin. 
The antivimentin/cardiolipin antibody complexes were 
found in a large proportion of patients with clinical fea-
tures suggestive of APS without criteria aPL patients 
tested and almost all those with APS [38]. These findings 
led the authors to consider vimentin as a new antigenic 
cofactor for aPL in APS and the vimentin/cardiolipin 
complex as a molecular target of the antibodies in APS 
patients. It is important to note, however, that antivimen-
tin/cardiolipin antibodies also have been detected in SLE 
and RA patients, so despite their high sensitivity, these 
antibodies are not very specific for APS.
Anti‑ annexin A5 and anti‑annexin 2 antibodies
Anti-AnxA5 antibodies (aAnxA5) have also been 
described in APS. Despite promising results observed in 
mice where aAnxA5 have been associated with placental 
thrombosis and fetal absorption [39], conflicting find-
ings have been observed concerning the association of 
aAnxA5 with a history of pregnancy-related morbidity 
in humans [40–42]. Similarly, de Laat et al. [43] did not 
observe any association between aAnxA5 and a history of 
thrombosis.
Annexin 2 is a cofactor for plasmin generation and 
cell-surface localization of fibrinolytic activity, (mainly 
monocytes, placental syncytiotrophoblasts and endothe-
lialium) [44, 45]. Cesarman-Maus et  al. were the first to 
describe the high prevalence of anti-annexin 2 antibodies 
in patients with APS [46]. Several observations might be in 
line with a pathogenic role for anti-annexin 2 antibodies in 
APS (e.g. induction of TF expression on endothelial cells; 
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second, prevention of placental annexin 2 from acting as 
a cofactor during plasmin generation) [39]. However, their 
clinical relevance remains a matter of debate and needs to 
be confirmed with experimental data as well as longitudi-
nal studies involving sufficient number of patients.
Thrombin generation assay and APS
A significant number of studies highlight that an altered 
thrombin generation may lead to pathologic processes, 
meanly haemorrhagic or thrombotic diseases [47]. 
Recent tests based on the continuous detection of throm-
bin generation under in  vitro conditions that mimic 
more closely what occurs in  vivo, has motivated a rein-
vestigation of the balance between pro-coagulants and 
anti-coagulants in patients with various haemostatic 
disorders. Furthermore, the evaluation of an individual’s 
thrombin-generation potential serves as a useful estima-
tor of the total coagulation potential, i.e. hyper- or hypo-
coagulability, when compared to traditional coagulation 
tests [48]. The clinical utility of thrombin generation tests 
however remains subject to highly specialised teams and 
is far from being used in standard clinical practice. How-
ever, TGA (thrombin generation assay) is a simple and 
reproducible technique that potentially can be used in 
coagulation laboratories. The test measures the amount 
of thrombin formed immediately after citrated plasma 
recalcification by adding exogenous activators (human 
recombinant tissue factors (TF) and phospholipids). 
Concentration of generated thrombin in the sample is 
recorded and then calculated from the fluorescence over 
time variation of the substrate, resulting in a thrombin 
generation curve. The following parameters are acquired: 
Lag time (tLag, time until thrombin burst), time to Peak 
thrombin generation (tPeak), peak amount of thrombin 
generation (Peak), velocity of thrombin generation (vel), 
and the total amount of thrombin generated (AUC, Area 
Under the thrombin generation Curve) [49].
The clinical utility of TGAs in assessing the thrombotic 
risk has been a matter of growing interest [47]. However, 
to date, TGA has been applied only for research purpose 
and its role in clinical practice still needs to be evaluated.
Few studies [50–53] described an association between 
an unbalance in TGA parameters and thrombotic risk 
in APS. Dienava-Verdoold et  al. [50] showed success-
ful cloning of patient-derived mAbs that require domain 
I of β2GPI for binding, and that display LA activity that 
is dependent on their affinity for β2GPI. When assessing 
the thrombin generation by using calibrated automated 
thrombography, it has been shown that lag time is influ-
enced by the presence of anti-β2GPI antibodies, and that 
the prolongation of the lag time was similar to the clot-
ting time prolongation observed in the dRVVT and the 
aPTT assay.
Regnault et  al. applied the thrombinography assessed 
by the conversion of a fluorogenic substrate in order to 
investigate the presence of acquired resistance to acti-
vated protein C (APC) in patients with LA [51]. They 
observed the complete process of thrombin formation 
and decay and its delimitation by the protein C system in 
eight consecutive LA-patients (all patients were not tak-
ing anticoagulation therapy). In 7 out of 8 patients they 
observed a long lag-time before the thrombin burst (LA 
effect) together with a marked inability of APC to dimin-
ish the thrombin activity. The lag-phase was however 
prolonged to some degree by APC when compared to 
controls. The effects were more evident in the presence 
of phospholipids from patients’ platelets than with added 
phospholipids. Thus, thrombinography demonstrates 
APC resistance in LA-patients despite the occurrence of 
long lag-times (clotting times).
These observations were confirmed by Zuily et al. [53] 
when they studied acquired APC resistance in patients 
with aPL using a TGA. A parameter summarizing APC 
inhibition of thrombin generation with increasing APC 
concentrations (IC(50)-APC) was increased in all patient 
groups compared to controls: median values were 15.3 
(interquartile range, IQR, 9.7–34.0) in patients with pri-
mary APS, 27.3 (IQR 23.5–43.5) in patients with SLE 
without APS, 64.1 (IQR 25.9–65.0) in patients with SLE/
APS compared to 10.4 [IQR 8.5–15.8] in controls, respec-
tively p = 0.003, p = 0.0001 and p = 0.0001.
More recently, Efthymiou et  al. [52] compared the 
degree of anticoagulation intensity in thrombotic APS 
and non-APS patients (50 in each group) on long-term 
warfarin. The group measured the INR with two widely 
available thromboplastins with instrument-specific ISI 
values in order to investigate the potential role of ami-
dolytic FX levels and thrombin generation. While there 
were no overall differences in INR between reagents or 
patient groups.
ETP and peak thrombin showed significant inverse cor-
relations with the INR, suggesting that TGA testing may 
be helpful in the determination of true anticoagulant 
intensity in APS patients, including those with ≥3.5 INR. 
Thrombin generation testing also highlighted a subgroup 
of APS patients with increased peak thrombin relative to 
the intensity of anticoagulation as assessed by INR and 
FX, supporting thrombin generation testing as a possi-
ble tool for the identification of ongoing prothrombotic 
states in patients on warfarin.
Overall, TGA seems a promising tool to further asses 
the thrombotic risk in patients with aPL; besides, TG 
testing may be useful in identifying subgroups of patients 
at higher risk such as those with an ongoing prothrom-
botic state and apparently adequate anticoagulation 
intensity as assessed by INR.
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Thrombotic risk assessment in aPL carriers and APS
aPL titres as well as their single, double or triple pres-
ence, have all been suggested to have a different distinct 
clinical significance [12, 13, 15, 17].
In general, the presence of aPL in individuals without 
any clinical manifestations, i.e. aPL carriers, can generally 
been seen as a risk factor for first time thromboembolic 
events [12]. LA has been shown to be a better predictor 
for thrombosis compared to any other aPL. In details, in 
2003 Galli et al. showed in a systematic review that LA is 
a strong risk factors for both arterial and venous throm-
bosis. The group assessed the risk of thrombosis associ-
ated with LA and aCL on studies including 753 patients 
and 234 controls and found a significant relation between 
LA and thrombosis with an OR ranging from 5.7 to 9.4 
aCL in turn was never associated with arterial or venous 
thrombotic events [54]. Of note, when the system-
atic review was performed, anti-β2GPI were routinely 
tested and the studies were performed prior to the latest 
amendment of the APS classification criteria where anti-
β2GPI was included into the criteria.
Conversely, De Groot et  al. showed in their Leiden 
cohort, that the presence of LA alone without the pres-
ence of anti-β2GPI (or antiprothrombin antibodies) was 
not significantly associated with a risk for a first DVT 
(OR 1.3, 95  % CI 0.3–6.0). However, in patients who 
tested positive for LA and anti-β2GPI antibodies (or anti-
prothrombin) the OR of a first time deep venous throm-
bosis increased to 10.1 (95 % CI 1.3–79.8) [9].
More recently, Pengo et al. showed that the presence of 
triple positive patients carries a higher risk of thrombosis 
(and adverse pregnancy outcome) compared to patients 
with positivity for only one aPL. The risk associated to 
the so-called ‘triple positivity’ (defined as the simultane-
ous positivity for LA, aCL and anti-β2GPI) was assessed 
in a study describing clinical outcomes of one hundred 
thirty-three patients after 1  year follow-up, 76 patient 
after 5  year follow-up and 23 patients after 10  year fol-
low-up. Over 30 % had a thromboembolic event during 
their follow up. Interestingly, there were more arterial 
events compared to venous events (25 had a venous 
thromboembolic event and 30 patients experienced an 
arterial event). However, it is worth noting that compli-
ance with regards to anticoagulation therapy was not 
specified [55].
Otomo et al. expanded on this principle and developed 
the aPL-score (aPL-s), with the aim to evaluate whether 
aPL titres influence the risk of thrombosis, comparing 
high to medium/low titres of aCL and anti-β2GPI IgG 
and IgM, respectively. The group showed that high levels 
of IgG aCL, anti-β2GPI (and also anti-phosphatidylserine 
and anti-prothrombin antibodies) were closely related 
to the clinical manifestations of APS. In their study the 
aPL-score related with a history of thrombosis or preg-
nancy morbidity. Moreover, the aPL-s score was shown 
to be of predictive value for the recurrence and/or new 
onset of thrombotic events [1]. These preliminary obser-
vations were independently validated [16].
Moving towards the concept of aPL as a risk factor, 
our group recently published a comprehensive series 
of studies developing and validating the global APS 
score (GAPSS) in different patients populations [2]. The 
GAPPS score combines independent risk factors for 
thrombosis and pregnancy loss, taking into account aPL 
profiles (criteria aPL and non criteria aPL), as well as con-
ventional cardiovascular risk factors and autoimmune 
antibody profiles.
Among all the computed variables (extensive aPL test-
ing, cardiovascular risk factors evaluation, autoimmune 
profile), multivariate logistic regression analysis showed 
that only arterial hypertension, hyperlipidaemia, LA, aCL 
IgG and/or IgM, anti-β2GPI IgG and/or IgM and aPS/PT 
IgG and/or IgM were independent risk factors for throm-
bosis and/or pregnancy morbidity. All variables were 
computed as dichotomized, in order make GAPSS more 
widely adoptable. aPL positivity was assessed according 
to the updated APS classification criteria [5].
The GAPSS includes IgG/IgM aCL (five points), IgG/
IgM anti-β2GPI (four points), LA (four points), IgG/IgM 
anti-phosphatidylserine-prothrombin complex antibod-
ies (three points), hyperlipedaemia (three points) and 
arterial hypertension (one point) (Table 2).
The GAPSS model was developed in patients with sys-
temic lupus erythematosus (SLE) and higher GAPS scores 
were observed in patients who experienced thrombosis 
and/or pregnancy loss compared with those without clin-
ical events. Moreover, the GAPSS score was evaluated in 
an other prospective study of 51 SLE patients [56] and 
in 62 consecutive patients with primary APS (PAPS) [3]. 
In both cohorts an increase in the GAPSS was found in 
patients who experienced thrombosis during the follow 
up period compared with those without events. Further-
more, higher GAPSS scores were observed in patients 
who experienced thrombosis compared with those with 
pregnancy morbidity alone. In more detail, patients with 
GAPSS values higher or equal of 11 were shown to have a 
higher risk of recurrences.
The GAPSS model was further applied and validated by 
two independent groups. Oku et al. [57] described, in a 
large cohort of rheumatologic patients, that APS mani-
festations (thrombosis or pregnancy morbidity) were 
experienced by patients with higher GAPSS values com-
pared to patients without APS manifestations. Recently, 
in another large cohort with APS and SLE patients, 
Zuily et  al. described mean GAPSS values significantly 
higher for patients who underwent a thrombotic event 
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compared to those who didn’t experienced a thrombotic 
event [53].
Conclusions and future research agenda
An individual thrombotic risk assessment and “risk strat-
ification” are fundamental for good clinical practice when 
evaluating patients with persistent aPL. Currently, this 
assessment is mostly limited to traditional cardiovascular 
and venous risk factors as well as aPL (LA test, aCL, and 
anti-β2GPI) profile. However, the field is moving towards 
better “risk stratification” given that new aPL tests, bio-
logic risk assessment, e.g., thrombin generation, and aPL-
specific thrombosis risk calculators have been studied 
in aPL-positive patients. Thus, future research agenda is 
promising and requires international collaboration.
AntiPhospholipid syndrome alliance for clinical tri-
als and InternatiOnal networking (APS ACTION) is the 
first-ever international research network that has been 
created specifically to design and conduct well-designed, 
large-scale, multicenter clinical studies in persistently 
aPL-positive patients.
Among other activities [58–61], in early 2012, APS 
ACTION launched an international clinical database and 
repository “registry” of persistently aPL-positive patients 
with or without systemic autoimmune diseases, which 
also includes annual blood collection for aPL-testing 
and future basic science studies. To date, the network is 
composed of 49 multidisciplinary physicians and investi-
gators interested in APS research from 29 international 
centers (www.apsaction.org). We believe that collabora-
tive efforts such as APS ACTION will help better define 
thrombosis risk assessment in APS.
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Table 2 The global antiphospholipid syndrome score 
(GAPSS)
Cardiovascular risk factors were assessed following National Institute for Health 
and Clinical Excellence guidelines (Excellence NIfHaC. Lipid modification: 
cardiovascular risk assessment and the modification of blood lipids for the 
primary and secondary prevention of cardiovascular disease. 2010. URL: http://
www.nice.org.uk/guidance/CG181 and Excellence NIfHaC. Hypertension. 2011. 
URL: http://www.nice.org.uk/guidance/QS28)
a aPL positivity was assessed according to the updated APS classification criteria 
[5]
b Serum total and high-density lipoprotein cholesterol levels were determined 
with standardized enzymatic methods and interpreted according to current 
cutoff values (total cholesterol of <5.0 mmol/l; <3.0 mmol/l for low-density 
lipoprotein cholesterol) (British Cardiac Society, British Hypertension Society, 
Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. 
JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease 
in clinical practice. Heart 2005; Suppl 5:v1–52)
c Arterial hypertension was defined as appropriately sized high blood pressure 
cutoff (140/90 mm Hg or higher) at least in two occasions or use of oral 
antihypertensive medications
Factor Point valuea




dylserine complex (aPS/PT) 
IgG/IgM
3
Cardiovascular risk factors Hyperlipidemiab 3
Arterial hypertensionc 1
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